eB2BMart

Rucaparib Bdparib 300 mg Tablets

₹32,000.00

Specification

form
Tablet
brand
Bdparib
storage
Store Below 30 Degree C
treatment
The treatment of prostate and ovarian cancers
composition
Rucaparib
availability
In Stock
dose strength
300 mg
medicine type
Allopathic
packaging type
Box
manufactured by
BDR Pharmaceuticals
Add Quantity
Response within 4 hoursFree to enquire

Description

Rucaparib to treat advanced ovarian and prostate cancers. BDPARIB is the first affordable generic in the India available in the form of a tablet, with the cost of therapy less expensive than any existing drugs in the market. Rucaparib is an oral, small-molecule inhibitor of poly (ADP-ribose) polymerase (PARP)1, 2, and 3 used as a monotherapy and in conjunction with other anti-cancer agents in several tumor forms, including ovarian and prostate cancers. It has played a significant role in treating ovarian cancer patients with BRCA mutation (germline or somatic) associated with epithelial ovarian, fallopian tube, or primary peritoneal cancer who have been treated with two or more chemotherapy.

Verify supplier credentials before transacting. Enquiries create leads for the supplier.

Rucaparib Bdparib 300 mg Tablets - ₹32,000.00 | Chawla Medicos | eB2bMart